Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
47,000
Employees47,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
47,000
Employees47,000

LLY Key Statistics

Market cap
974.15B
Market cap974.15B
Price-Earnings ratio
50.53
Price-Earnings ratio50.53
Dividend yield
0.57%
Dividend yield0.57%
Average volume
5.18M
Average volume5.18M
High today
$1,040.72
High today$1,040.72
Low today
$1,013.45
Low today$1,013.45
Open price
$1,017.39
Open price$1,017.39
Volume
3.43M
Volume3.43M
52 Week high
$1,040.72
52 Week high$1,040.72
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 974.15B, Eli Lilly(LLY) trades at $1,028.94. The stock has a price-to-earnings ratio of 50.53 and currently yields dividends of 56.8%.

During the trading session on 2025-11-18, Eli Lilly(LLY) shares reached a daily high of $1,040.72 and a low of $1,013.45. At a current price of $1,028.94, the stock is +1.5% higher than the low and still -1.1% under the high.

Trading volume for Eli Lilly(LLY) stock has reached 3.43M, versus its average volume of 5.18M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,040.72 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,040.72 and a low of $623.78.

LLY News

The Wall Street Journal 2h
Lilly Stock Continues Its Winning Ways

Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lil...

Lilly Stock Continues Its Winning Ways
Simply Wall St 2h
Are Direct-to-Consumer Channels Reinforcing Eli Lilly’s Competitive Edge in the Obesity Market?

Mangoceuticals, Inc. recently announced the launch of MangoRx Direct and PeachesRx Direct programs, offering direct access to Eli Lilly's Zepbound and Novo Nord...

Are Direct-to-Consumer Channels Reinforcing Eli Lilly’s Competitive Edge in the Obesity Market?
MarketWatch 2h
Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Eli Lilly’s weight-loss drug Zepbound is on track to be the world’s top-selling drug, and Lilly is inching closer to a $1 trillion market cap. Biopharma is bac...

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Analyst ratings

74%

of 31 ratings
Buy
74.2%
Hold
22.6%
Sell
3.2%

More LLY News

Nasdaq 2h
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?

Key Points Weight loss pills could account for 25% of the market share over the long term. The GLP-1 market is expected to grow to $100 billion by 2030. New...

Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle?
Seeking Alpha 8h
Eli Lilly's donanemab gets approval in India for Alzheimer's treatment

Eli Lilly’s (LLY) Alzheimer’s disease drug, donanemab, has been approved by India’s drug regulator and is expected to be launched within the next few months. D...

Eli Lilly's donanemab gets approval in India for Alzheimer's treatment
TipRanks 10h
Eli Lilly price target raised to $1,150 from $1,050 at JPMorgan

JPMorgan analyst Chris Schott raised the firm’s price target on Eli Lilly (LLY) to $1,150 from $1,050 and keeps an Overweight rating on the shares after meeting...

The Wall Street Journal 13h
The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company

Eli Lilly now captures a clear majority of new obesity-drug prescriptions. Peter Byrne/Zuma Press The trillion-dollar club has become crowded with mostly tech...

The Weight-Loss Craze Is About to Mint a Trillion-Dollar Company
Zacks 14h
The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum

This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herei...

The Zacks Analyst Blog Highlights Eli Lilly, Johnson & Johnson and Adverum
Nasdaq 21h
Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?

Key Points Pfizer's CEO thinks his company will make big waves in the weight loss market. Eli Lilly does have a strong hold on the industry and won't let go a...

Pfizer's CEO Sends a Warning to Eli Lilly. Is the Stock a Buy?
Benzinga 1d
Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring

Something big is happening in healthcare, as pharma stocks have recently rallied on breakthrough AI developments that could reshape the entire industry. The He...

Is AI The Key To Beating Cancer? Why Pharma Stocks Are Soaring

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.